Inloggad som:
HOVON 173
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
HOVON 173
Fastställa specifika egenskaper hos blodceller för eventuellt deltagande i en HOVON-studie för behandling av akut myeloisk leukemi (AML) eller myelodysplastiskt syndrom (MDS).
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Skånes universitetssjukhus / Hematologisk vård
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Mer information om studien för vårdgivare
1. Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML according to the
2022 International Consensus Classification (Appendix A). Patients with AML with both IDH1 and
IDH2 mutation are eligible as well. (for more info see link)
1. Subject has previously been treated for AML; a treatment period with hydroxyurea to control
WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed;
prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed. (for info see link)
Behandling
Fas 3
Kurativ
Ej tillämpbar
Ej tillämpbar
Studien ändrades senast: (2025-10-02)